|Bid||13.38 x 3100|
|Ask||13.50 x 1000|
|Day's range||13.08 - 13.39|
|52-week range||12.98 - 23.25|
|Beta (5Y monthly)||1.01|
|PE ratio (TTM)||15.73|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||07 Oct 2008|
|1y target est||N/A|
CHICAGO, March 14, 2023--Veradigm® (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Veradigm Practice Management first for its 2023 Practice Management Solutions, 50+ Physician Groups category.
CHICAGO, February 28, 2023--Veradigm Inc. (NASDAQ: MDRX), announced today that in conjunction with its year-end audit procedures it has detected certain internal control failures related to revenue recognition that have occurred over the prior six quarters, resulting in a mis-statement to reported revenues during those periods. As a result, the Company and its external auditors need to expand procedures and are filing with the SEC a Form 12b-25, extending the due date of the Company’s Form 10-K
CHICAGO, February 22, 2023--Susan Rodriguez and Shih-Yin Ho, MD have been named to the Board of Directors of Veradigm Inc. (NASDAQ: MDRX). With their combined experience in the pharmaceutical industry, digital health, and healthcare, together they bring a wealth of experience to Veradigm, to help build upon the company’s vision of transforming health, insightfully.